The liver represents the third most frequent site of metastasis in patients with breast cancer. We performed in vivo selection using 4T1 breast cancer cells to identify genes associated with the liver metastatic phenotype. Coincident with the loss of numerous tight-junctional proteins, we observe claudin-2 overexpression, specifically in liver-aggressive breast cancer cells. We further demonstrate that claudin-2 is both necessary and sufficient for the ability of 4T1 breast cancer cells to colonize and grow in the liver. The liver-aggressive breast cancer cells display a claudin-2-mediated increase in their ability to adhere to extracellular matrix (ECM) components, such as fibronectin and type IV collagen. Claudin-2 facilitates these cell/matrix interactions by increasing the cell surface expression of a 2 b 1 -and a 5 b 1 -integrin complexes in breast cancer cells. Indeed, claudin-2-mediated adhesion to fibronectin and type IV collagen can be blocked with neutralizing antibodies that target a 5 b 1 and a 2 b 1 complexes, respectively. Immunohistochemical analyses reveal that claudin-2, although weakly expressed in primary human breast cancers, is readily detected in all liver metastasis samples examined to date. Together, these results uncover novel roles for claudin-2 in promoting breast cancer adhesion to the ECM and define its importance during breast cancer metastasis to the liver.
Introduction
Progression to metastatic disease is the principal cause of mortality in breast cancer patients (Berkowitz et al., 2000; Ugnat et al., 2004) . Breast cancer cells preferentially metastasize to specific organs and tissues, with the liver representing the third most frequent site following bone and lung (Clark et al., 1987; Insa et al., 1999) . Breast cancer patients with liver metastases display a poor prognosis, with median survival times between 14 and 20 months and 5-year survival rates that reach only 5.5-8.5% (Pentheroudakis et al., 2005; Eichbaum et al., 2006) . However, little is known about the molecular mechanisms governing the spread and growth of breast cancer cells in the liver.
In normal epithelia, tight junctions provide a critical barrier function between adjacent cells by creating a tight seal that regulates the paracellular movement of water, solutes and macromolecules (Turksen and Troy, 2004) . The loss of tight-junctional components is frequently observed in epithelial-derived cancers and disruption of cell-cell adhesions correlates with breast cancer progression, invasion and metastasis (Martin et al., 2004; Osanai et al., 2006; Naik et al., 2008) . Claudins are key transmembrane proteins within the tight junction complex that participate in homo-and heterotypic interactions between adjacent cells (Turksen and Troy, 2004) . Potential roles for claudin proteins in breast cancer progression are complex. Some studies demonstrate the loss of specific claudins during breast cancer progression, whereas others suggest that overexpression of particular claudins are associated with poor outcome in breast cancer patients (Martin and Jiang, 2009 ). For example, some breast cancers exhibit a loss of claudin expression, including claudin-1, -2 and -7 (Kominsky et al., 2003; Sauer et al., 2005; Tokes et al., 2005; Kim et al., 2008) , whereas claudin-3 and -4 can be overexpressed in human breast cancers, particularly in the triple-negative subtype (Kominsky et al., 2004; Blanchard et al., 2009; Kulka et al., 2009; Lanigan et al., 2009) . Although these studies, which are focused on claudin expression in the primary tumor, suggest that specific claudin proteins may fulfill tumor-suppressor or tumor-promoting roles in breast cancer, little is known regarding claudin expression in breast cancer metastases.
Conflicting roles for claudin-2 in cancer have also been proposed. In breast cancer, claudin-2 expression has been shown to be downregulated in breast tumors compared with normal tissue, and diminished levels of claudin-2 are observed in breast cancers of increasing grade, arguing that claudin-2 has a tumor-suppressive role in breast cancer (Kim et al., 2008) . In contrast, claudin-2 is important for the invasive characteristics of gastric carcinomas and its overexpression is observed in colorectal cancers, two types of cancer that preferentially metastasize to the liver (Aung et al., 2006; Kinugasa et al., 2007) . Recently, claudin-2 was shown to be a critical mediator of symplekin-induced colorectal cancer cell proliferation and anchorage-independent growth (Buchert et al., 2010) . Thus, in certain cancers, claudin-2 also displays tumor-promoting properties.
In the current study, we demonstrate that claudin-2 expression, in conjunction with the loss of tight-junction components, is characteristic of liver metastatic breast cancer cells. Our results demonstrate a functional requirement for claudin-2 in promoting breast cancer metastasis to the liver through a mechanism that may involve enhanced integrin-mediated cell adhesion.
Results
In vivo selection of liver metastatic 4T1 breast cancer cells Using a splenic injection approach, 4T1 cells were subjected to an in vivo selection protocol designed to isolate sub-populations that grow aggressively in the liver (Supplementary Figure 1a) . Sub-populations were identified that progressively acquired a liver-aggressive phenotype (Supplementary Figures 1b and c) . Following three consecutive rounds of selection, three cell populations (2776, 2792 and 2869) exhibited increased outgrowth in the liver and represent aggressively livermetastatic populations (Figures 1a and b) . Two cell populations (2648 and 2801) were isolated with a liver outgrowth phenotype similar to parental 4T1 cells and represent a weakly liver metastatic group (Figures 1a  and b) . The liver-aggressive breast cancer populations occupied 35-39% of the cardiac liver lobe compared with only 6-14% observed following injection of the less aggressive cells (Figure 1b) . Thus, three rounds of in vivo selection were sufficient to isolate 4T1 breast cancer cells that displayed an enhanced ability to colonize and grow in the liver.
Liver-aggressive 4T1 sub-populations display a diminished capacity to metastasize to lung but enhanced liver metastasis from the primary site We first determined whether the liver-aggressive 4T1 subpopulations possessed an increase in their general growth characteristics. No significant change in mammary tumor outgrowth was observed between weakly and highly liver-aggressive breast cancer cells (Figure 1c) . However, liver-aggressive cells demonstrated an average 3.6-fold decrease in their spontaneous lung metastatic potential, coincident with an average 15-fold increase in the frequency of spontaneous hepatic metastases compared with breast cancer cells that are weakly metastatic to the liver (Figure 1d) . Thus, the liver-aggressive in vivo selected populations do not display a general increase in their growth or metastatic abilities, but confer a selective advantage to metastasize and grow in the liver.
Gene expression profiling reveals a loss of adhesion molecules in liver metastatic populations To identify mediators that contribute to the liver metastatic phenotype, we performed gene expression profiling using Agilent whole mouse genome microarrays (Agilent Technologies, Wilmington, DE, USA) and defined differentially expressed genes associated with the liver metastatic phenotype. This analysis revealed 210 differentially expressed genes between the two groups (71 genes with elevated expression and 139 genes with reduced expression in the liver-aggressive cells) (Supplementary Tables 1 and 2 ). Several genes associated with cell-cell adhesion were identified as differentially expressed between the two groups, including Mpzl2 (epithelial V-like antigen-1), Dsg2 and the tight-junctional components Cldn7, Cldn23 and Ocln, which were downregulated in highly-aggressive cell lines (Supplementary Table 2 ). Interestingly, in the context of diminished expression of genes encoding cell-cell adhesion molecules, Cldn2 was upregulated in the liveraggressive breast cancer cells (Supplementary Table 1 ).
Liver-aggressive breast cancer populations have lost expression of tight-junction components with a concomitant increase in claudin-2 expression levels By quantitative real time PCR, we confirmed that Mpzl2, Dsg2, Cldn7 and Ocln mRNA expressions were significantly reduced in the liver-aggressive versus the liver-weak breast cancer cell populations (Supplementary Figure 2 and data not shown). Cldn2 transcripts were overexpressed in all liver-aggressive populations in relation to their liver-weak counterparts (Supplementary Figure 2) . We extended these analyses to additional tight-junction components and discovered that, among them, Cldn3 and Cldn4 were underexpressed in a similar manner as Cldn7 (Supplementary Figure 2) .
Immunoblot analysis on all six 4T1-derived populations confirmed that claudins-3, -4, -7 and occludin were lost at the protein level in all three liver-aggressive populations, in accordance with the mRNA expression data (Figure 2a) . Moreover, claudin-2 protein was also found to be highly expressed in the three liver-aggressive cell populations (Figure 2a ). Our results demonstrate that a marked loss of several tight-junctional components, concomitant with an increase in claudin-2 levels, is characteristic of the in vivo selected liver-aggressive 4T1 subpopulations.
Claudin-2 and breast cancer liver metastasis S Tabariès et al Claudin-2 expression enhances the liver-aggressive phenotype To examine whether claudin-2 can enhance the liver metastatic phenotype, we stably overexpressed claudin-2 in weakly aggressive breast cancer cells and generated pooled expressors for further analysis (Supplementary Figure 3a) . Importantly, claudin-3, -4, -7 and occludin expression levels were not affected by claudin-2 overexpression (data not shown). Following splenic injection, claudin-2 overexpressing cells showed greater numbers of liver surface lesions and a higher tumor burden in the liver when compared with their respective empty vector (EV) controls (Supplementary Figure 3b) . Moreover, lesions formed by claudin-2 overexpressing cells occupied 3-3.5 times more of the liver area when compared with control cells (Supplementary Figure 3c and d) .
We next stably diminished claudin-2 levels in two liveraggressive cell populations using a short hairpin RNA (shRNA)-mediated approach (Figure 2b ). Although no significant change in mammary tumor outgrowth was observed in liver-aggressive cell populations with diminished claudin-2 levels (Supplementary Figure 4) , reduced claudin-2 expression was sufficient to diminish the number of liver surface lesions and liver tumor burden compared with their respective EV or parental controls (Figures 2c and d) . Breast cancer cells with diminished claudin-2 levels occupied 2-9 times less liver area when compared with control cells (Figures 2c and d) . Together, these data demonstrate that claudin-2 is functionally involved in breast cancer cell outgrowth in the liver.
Claudin-2 does not induce the invasive phenotype that characterizes the liver-aggressive 4T1 explants The loss of tight-junctional components is associated with enhanced migratory and invasive characteristics of cancer cells (Osanai et al., 2007; Naik et al., 2008) . The role of claudin-2 in mediating these processes is unclear given that claudin-2 overexpression has been associated with enhanced invasiveness of gastric cancers (Mima et al., 2008) , whereas other reports suggest that claudin-2 expression correlates with decreased invasion of breast cancer cells (Thakur et al., 2008) . To address this issue, we first demonstrated that our in vivo selected liveraggressive breast cancer cells are significantly more motile and invasive when compared with the liver-weak sub-populations ( Supplementary Figures 5 and 6 ). We further characterized the role of claudin-2 in these processes. We observed only a modest 1.3-fold increase in the in vitro motility of claudin-2 expressing cells compared with vector controls (Supplementary Figure  7a) . Moreover, no significant differences were observed in the in vitro invasive properties associated with these cell populations (Supplementary Figure 7b) . Although reduced claudin-2 expression results in a 1.6-2.4-fold attenuation of wound closure, it does not significantly alter the in vitro invasive properties of liver-aggressive breast cancer cells (Supplementary Figure 7c, d) . Thus, the importance of claudin-2 in promoting the establishment and growth of breast cancer liver metastases cannot be attributed to a role in promoting the invasion of liver-aggressive sub-populations. Claudin-2 and breast cancer liver metastasis S Tabariès et al
Claudin-2 expression promotes adhesion of liver-aggressive breast cancer cells to fibronectin and type IV collagen Another mechanism by which claudin-2 could facilitate breast tumor outgrowth in the liver is by enhancing cancer cell adhesion and/or survival in this organ. The endothelial lining of the liver sinusoids possesses numerous fenestrae or small pores and lacks a basal lamina, two features which are uncharacteristic of vessels found in other organs and tissues (Braet and Wisse, 2002; Wisse et al., 2008; Yokomori, 2008; Braet et al., 2009) . Therefore, tumor cells would immediately interact with underlying extracellular matrix (ECM) proteins and not basement membrane components such as laminins. In the adult liver, the sub-sinusoidal ECM is characterized predominantly by the presence of fibronectin and, to a lesser extent, type IV collagen (Martinez-Hernandez and Amenta, 1993) . Indeed, integrin-mediated adhesion to the ECM has an extremely important role in the ability of colon cancer cells to establish and grow in this organ (Kemperman et al., 1995; Enns et al., 2004; Schluter et al., 2006) . We, therefore asked whether claudin-2 upregulation enhanced ECM adhesion. Using a cell attachment assay, we demonstrate that liver-aggressive cells display a higher propensity to adhere to fibronectin or type IV collagen-coated plates compared with their weakly liver-aggressive counterparts ( Figure 3a) . No significant differences were observed when cells were plated on type I collagen-or laminin-coated plates (data not shown). We further demonstrate that claudin-2 is required for the ability of liver-aggressive breast cancer cells to adhere to fibronectin or type IV collagen (Figure 3b ). Moreover, expression of claudin-2 is sufficient to enhance the adhesive properties of weakly liver-aggressive cells onto these ECM components (Supplementary Figure 8) .
To evaluate an independent cell line that endogenously expresses claudin-2; we screened a panel of breast cancer cells for the expression of various claudins Claudin-2 and breast cancer liver metastasis S Tabariès et al ( Figure 4a ). MDA-MB-231 cells displayed a similar pattern of claudin expression present in our in vivo selected 4T1-derived liver-aggressive cell lines, with expression of claudin-2 and loss of claudin-3 and -7. However, unlike the liver-aggressive 4T1 cells, the MDA-MB-231 cells express claudin-4 (Figure 4a ). Using two different shRNA target sequences, we have generated cell lines in which claudin-2 expression was greatly reduced relative to parental and EV control cells (Figure 4b ). Importantly, claudin-4 expression levels were not affected by diminished claudin-2 expression, indicating that the shRNAs displayed specificity against claudin-2 (Supplementary Figure 9 ). In an attachment assay, diminished claudin-2 expression resulted in an average 2.1-or threefold reduction in the ability of MDA-MB-231 cells to adhere to fibronectin and type IV collagen, respectively (Figure 4c) , reminiscent of the results obtained with 4T1-derived cells (Figure 3b ). These results suggest that claudin-2 facilitates tumor cell adhesion to fibronectin or type IV collagen.
Claudin-2 enhances a 2 b 1 -and a 5 b 1 -integrin complexes formation on the cell surface We next assessed whether claudin-2 could contribute to cell adhesion by influencing the formation of a 2 b 1 or a 5 b 1 complexes, which are integrin receptors for type IV collagen or fibronectin, respectively. Although no changes in the expression levels of individual a-or b-integrin chains were observed in the presence or absence of claudin-2 (Figure 5a ), we observed that claudin-2-deficient MDA-MB-231 cells possessed a 2-to 4-fold reduction in a 2 b 1 -and a 5 b 1 -integrin complexes at the cell surface, as assessed by flow cytometry, relative to vector control cells (Figure 5b and Supplementary  Figure 10 ). Using blocking antibodies against either a 2 b 1 or a 5 b 1 complexes, we further confirmed that the adhesion to fibronectin and type IV collagen exhibited by MDA-MB-231 cells is indeed mediated by the formation of such integrin complexes (Figure 5c ). Indeed, preincubation with 1.0 or 1.5 mg of neutralizing antibodies directed against a 2 b 1 resulted in a 2.1-and 2.9-fold reductions in breast cancer cell adhesion to type IV collagen, respectively, with much less effect on cancer cell adhesion to fibronectin (Figure 5c ). Conversely, addition of 0.5 or 1.0 mg of a 5 b 1 neutralizing antibodies caused a fourfold reduction in breast cancer cell adhesion to fibronectin, with a less pronounced affect on the adhesion of these cells to type IV collagen (Figure 5c ). These data indicate that the enhanced adhesion displayed by claudin-2-expressing breast cancer cells relies on the function of a 2 b 1 -or a 5 b 1 -integrin Figure 3 Claudin-2 expression enhances attachment to type IV collagen and fibronectin. (a) The number of liver-weak versus liveraggressive breast cancer cells that adhered to type IV collagen or fibronectin-coated plates was quantified. Statistically significant increases in adhesion were observed in all liver-aggressive explants. Owing to the large variability in cell size and shape exhibited by the explant populations, the average pixel count from five independent images was first quantified using Imagescope software (Aperio). We next calculated the average pixel count of one cell, using five randomly selected individual cells within a field. The data is expressed as an approximate number of cells per field (total pixel count/pixel count for one cell). (b) Diminished claudin-2 levels in liver-aggressive 4T1 cells decreases their ability to attach to type IV collagen or fibronectin-coated plates.
Claudin-2 and breast cancer liver metastasis S Tabariès et al Claudin-2 and breast cancer liver metastasis S Tabariès et al complexes. Together, these results suggest that claudin-2 may facilitate the recruitment and/or assembly of functional fibronectin and collagen IV receptors onto the cell surface, and thus enhance breast cancer cell adhesion to these ECM components.
Claudin-2 is expressed in liver metastases from breast cancer patients We next examined the potential relevance of claudin-2 in the human disease using clinical samples of primary breast tumors and liver metastases. Claudin-2 expression has been shown to be lost in primary breast cancers compared with normal tissue, and lower claudin-2 expression was characteristic of higher tumor grade (Kim et al., 2008) . In agreement with these previous observations, we found that 75% of primary human breast tumors (12/16) were negative or weakly positive (0, þ 1) for claudin-2 by immunohistochemical staining (Figure 6 and Supplementary Table 3 ). However, claudin-2 expression levels in liver metastases from breast cancer patients remains currently undefined. Therefore, we obtained 22 liver resection specimens and two biopsy samples from breast cancer patients diagnosed with hepatic metastases. Immunohistochemical staining of these samples with a claudin-2 antibody revealed moderate-to-strong claudin-2 staining in 58% ( þ 2, þ 3; 14/24) of the liver metastases, whereas 42% displayed lower claudin-2 levels ( þ 1; 10/24) ( Figure 6 and Supplementary Table 3) . Together, our results argue that claudin-2 expression, although lost in highgrade primary tumors, may be selected for and contribute to the ability of breast cancer cells to metastasize to the liver.
Discussion
We have utilized a mouse model system to identify candidate genes involved in liver metastases, highlighting claudin-2 as a potential mediator of breast cancer liver metastasis. Interestingly, claudin-2 expression occurs in the context of diminished expression of numerous tight-junctional components. A current and prevailing view is that tight junctions are frequently disrupted during cancer progression, which results in the manifestation of aggressive cancer phenotypes such as reduced cell-cell cohesion and increased migration and invasion (Morin, 2005) . Indeed, all of our 4T1-derived populations fail to form monolayers capable of barrier function, as assessed by transepithelial resistance measurements, indicating that functional tight junctions are not formed in 4T1 cells (data not shown). Thus, our data cannot be simply explained by the loss of functional tight junctions in our liver-aggressive versus liver-weak breast cancer cells. We observe a selection for the loss of occludin and claudins-3, -4 and -7 in the liveraggressive breast cancer cell populations. These observations are consistent with a loss of claudin-1 and -7 expression in primary breast cancers of increasing grade (Kramer et al., 2000; Kominsky et al., 2003; Sauer et al., 2005) . Our results are also in agreement with a recent publication demonstrating the loss of cell adhesion molecules, including claudin-4 and claudin-7, in 4T1 sub-populations that are metastatic to the liver (Erin et al., 2009) . Finally, a 'claudin-low' subtype has recently been identified in 13 primary human breast cancers that possess features that are both similar to but distinct from the previously defined basal subtype (Herschkowitz et al., 2007) . This subtype is characterized Figure 6 Claudin-2 expression is enriched in human breast cancer liver metastases compared with primary tumors. Paraffinembedded sections from primary breast tumors (n ¼ 16) and liver specimens from breast cancer patients with hepatic metastases (n ¼ 24) were subjected to immunohistochemical staining with anti-claudin-2 antibodies. Representative images from each category (0, þ 1, þ 2, þ 3) are shown. No liver metastases were scored as 0 for claudin-2 staining. Scoring of claudin-2 staining (percentage positivity and intensity) was performed by two independent reviewers (see Supplementary Table 3 ). The percentage of samples scored in each category (0, þ 1, þ 2, þ 3) is shown (Po0.005, value is derived from a comparison of the primary tumor samples versus liver metastasis samples). Inset panels illustrate claudin-2 staining in normal breast epithelium adjacent to the tumor (upper panels) or in the liver parenchyma adjacent to the metastases (lower panels) as positive controls for the immunohistochemistry reaction. Scale bars, 50 mm.
Claudin-2 and breast cancer liver metastasis S Tabariès et al by features of an epithelial-to-mesenchymal transition, enhanced stem cell characteristics and resistance to chemotherapy (Creighton et al., 2009 (Creighton et al., , 2010 Hennessy et al., 2009; Prat et al., 2010; Taube et al., 2010) . At the present time, the status of claudin-2 expression within these 'claudin-low' tumors has not been described. We have demonstrated that claudin-2 expression is specifically elevated in liver-aggressive breast cancer cells and promotes their ability to metastasize to the liver. There is precedence for the upregulation of specific claudins in breast cancer, including claudin-3 and -4, which have been correlated with the poor prognosis, basal breast cancer subtype (Blanchard et al., 2009; Kulka et al., 2009; Lanigan et al., 2009) . Thus, the metastatic phenotype of breast cancer cells can be influenced by the specific claudin in question and the context in which it is expressed.
We show that claudin-2-mediated effects on breast cancer liver metastasis may, in part, involve enhanced adhesion to ECM components, such as fibronectin or type IV collagen, that are abundant in the liver. Moreover, the ability of claudin-2 to confer enhanced breast cancer adhesion to ECM components may result from its ability to promote membrane localization of integrin complexes that bind these ECM proteins, including a 2 b 1 and a 5 b 1 . The ability of claudin proteins to modulate integrinmediated adhesion is likely to be indirect. In this regard, tetraspanins are essential for adhesion strengthening of integrin-containing complexes and individual tetraspanins have been found in complexes with numerous integrin partners (Hemler, 2005; Lazo, 2007) . Interestingly, claudins have been shown to interact with tetraspanin molecules. For example, claudin-11 interacts with OAP-1 to form a complex with integrins, which results in increased oligodendrocyte proliferation and migration (Tiwari-Woodruff et al., 2001) . In addition, claudin-7 has been shown to form a complex with tetraspanins, EpCam and CD44 in colorectal cancers, and expression of these molecules was inversely correlated with disease-free survival (Kuhn et al., 2007) . Interestingly, we performed immunofluorescence staining for claudin-2 in MDA-MB-231 cells and found that claudin-2 displays a punctate staining pattern when cells are plated on fibronectin (data not shown). This claudin-2 staining does not overlap with phospho-FAK, which was used as a marker for focal adhesions (data not shown). This pattern of claudin-2 staining is reminiscent of tetraspanin-integrin localization, which also has previously been shown to be distinct from focal adhesions (Berditchevski and Odintsova, 1999; Penas et al., 2000; Yanez-Mo et al., 2001; Berditchevski et al., 2002) . Thus, it is conceivable that claudin-2 interacts with integrin/tetraspanin-containing complexes in liver metastatic breast cancer cells to facilitate adhesion and survival in this organ.
The ability of claudin-2 to enhance breast cancer cell adhesion is not a reflection of increased expression of individual a 2 , a 5 or b 1 subunits, but rather the recruitment of a 5 b 1 -and a 2 b 1 -integrin complexes to the cell surface. Our liver-aggressive cells also showed an enhanced ability to interact with type IV collagen. The a 2 b 1 -integrin, which can interact with type IV collagen (Magro et al., 1997; Friedrichs et al., 2008) , has been associated with gastric cancer carcinoma lymph node and liver metastasis (Ura et al., 1998) . The use of an antagonist of a 2 b 1 has been reported to decrease the extravasation into the liver and micrometastasis associated with colorectal and hepatocellular carcinoma cell lines (Rosenow et al., 2008) . Finally, a recent study has demonstrated that the a 2 -integrin, which was specifically upregulated within in vivo selected liver-metastatic B16 melanoma cell lines, mediated liver metastasis through binding to type IV collagen and activation of FAK (Yoshimura et al., 2009) . However, in our model, no changes in a 2 -integrin expression levels or FAK activation have been observed (data not shown).
Claudin-2 expression has been demonstrated in 52% of breast carcinomas (Soini, 2004) . In agreement with these published observations, our present results revealed weak claudin-2 positivity in 62.5% of primary human breast tumors. Moreover, claudin-2 expression has been shown to be downregulated in invasive ductal carcinomas and loss of claudin-2 expression is associated with lymph node metastasis and high tumor grade, suggesting a role for claudin-2 as a potential tumor suppressor (Kim et al., 2008) . However, this latter study examined only normal mammary gland and primary tumor material and did not evaluate claudin-2 expression in metastatic lesions. To address this issue, we utilized liver resection specimens and biopsy material from patients with breast cancer liver metastases. Few patients meet the criteria for partial hepatic resection for breast cancer liver metastases (Selzner et al., 2000; Er et al., 2008; Diamond et al., 2009 ); however, we were able to analyze 24 breast cancer liver metastases. Importantly, our data indicates that claudin-2 is expressed in all liver metastases from breast cancer patients. Together, our results raise the possibility that reduced claudin-2 expression may be a general feature of the transition to neoplasia at the primary site, but is expressed in metastatic breast cancer cells capable of colonizing and growing in the liver. Within the set of clinical samples that we analyzed, two represented matched sets of primary breast tumor and the derived liver metastases (patients 1 and 2). Interestingly, claudin-2 staining was found to be more uniform and stronger in the liver metastases compared with the matched primary tumor in both cases. The sites of relapse were known in the majority of these patients; however, no correlation was found between claudin-2 expression in the primary tumor and preferential relapse to the liver. This may suggest that claudin-2 expression is regained in breast cancer cells that colonize the liver or, alternatively, small numbers of claudin-2 positive breast cancer cells within the primary tumor were able to disseminate to the liver.
Our studies are the first to identify Cldn2 as a gene selectively overexpressed in breast cancer cells that are metastatic to the liver and demonstrate a functional role for claudin-2 in this process. Interestingly, the expression of claudin-2 occurred in the context of an overall reduction in the expression of numerous tight junction components. Thus, whether claudin expression is Claudin-2 and breast cancer liver metastasis S Tabariès et al associated with tumor suppressive versus prometastatic effects within cancer cells may reflect the status of additional junctional proteins within the cell. Future studies will address mechanisms through which claudin-2 functions, outside of its role in tight junctions, to promote integrin complex formation, cell adhesion and breast cancer liver metastasis.
Materials and methods

Cell culture and transfections
The 4T1 and MDA-MB-231 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as previously described (Rose et al., 2007; Mourskaia et al., 2009) . Cldn2 knockdown was achieved using the LMP vector system from a microRNA-30-adapted shRNAmir retroviral vector kit, following the manufacturer's protocol (Open Biosystems, Huntsville, AL, USA). See Supplementary Methods for shRNA sequences.
Experimental and spontaneous metastasis assays
For experimental metastasis assays, 4T1 cells were injected into the spleens of 4-to 6-week-old female Balb/c mice as previously described (Fidler, 1986; Giavazzi et al., 1986) . For spontaneous metastasis studies, 1 Â 10 5 cells were injected and tumor volumes determined as previously described (Rose et al., 2007) . The number of surface lesions was scored over all lobes of the liver and lungs before paraffin embedding. Tumor burden in the liver (left cardiac lobe) and lungs was quantified from four hematoxylin & eosin stained step sections (200 mm/step). The number of lesions per section and the tumor area/tissue area were quantified using Imagescope software (Aperio, Vista, CA, USA).
Immunoblotting
Membranes were processed as previously described (Northey et al., 2008) and subjected to immunoblot analysis using the following antibodies at a dilution of 1:5000: claudin-2, claudin-3, claudin-4, claudin-7 and occludin (Invitrogen, Burlington, ON, Canada), a 1 -, a 2 -, a 5 -, a v -, b 1 -, b 2 -, b 3 , b 4 -integrins (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a-tubulin (Sigma, Oakville, ON, Canada). Blots were incubated with horseradish-peroxidase-conjugated anti-IgG secondary antibodies (Jackson ImmunoResearch Laboratories, Bar Harbor, ME, USA) and visualized with chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA).
Immunohistochemistry
Unstained sections (4 mm) were subjected to antigen retrieval in 10 mM citrate buffer (pH 6.0) for 10 min at sub-boiling temperatures. Slides were incubated overnight at 4 1C with a rabbit anti-claudin-2 antibody (1:25 dilution, Invitrogen). Following incubation with the primary antibody, secondary biotin-conjugated antibody was applied for 30 min. After washing with phosphate-buffered saline (PBS), slides were developed with diaminobenzidine (Dako, Mississauga, ON, Canada) as the chromogen. All slides were counterstained using Harris haematoxylin. All slides were visualized by light microscopy and scored by two independent reviewers (Supplementary Table 3 ).
Cell attachment assays
To assess the ability of 4T1 and MDA-MB-231 breast cancer cells to adhere to fibronectin, laminin, type I collagen or type IV collagen, 1 Â 10 5 cells were seeded onto precoated 24-well plates (BD Biosciences, Mississauga, ON, Canada) and incubated for 1 h at 37 1C. The plates were rinsed twice with PBS and adherent cells were fixed, stained and quantified as described for the motility and invasion assays (Supplementary Methods). For attachment assays using integrin complex blocking antibodies, trypsinized cells (5 Â 10 5 ) suspended in PBS were incubated on ice for 45 min using increasing concentration of a 2 b 1 or a 5 b 1 blocking (Millipore) or isotype control antibody (BD Biosciences).
Flow cytometric analysis of cell surface a 2 b 1 -or a 5 b 1 -integrin expression Trypsinized cells (5 Â 10 5 ) suspended in PBS containing 1% fetal bovine serum were stained on ice for 45 min using 10 mg/ ml of a 2 b 1 , a 5 b 1 (Millipore) or isotype control (BD Biosciences) antibodies. After washing with fetal bovine serum-containing PBS, cells were stained with Alexa fluor 555-conjugated goat anti-mouse F(ab) 2 fragments (Invitrogen). After three subsequent washing steps, 1 Â 10 4 cells were assessed for cell surface expression of a 2 b 1 or a 5 b 1 using a FACScan flow cytometer (BD Biosciences). The compound, 7-AAD (BD Biosciences) was added to discriminate live from dead cells.
Statistical analysis
Significance values associated with differences in adhesion to type IV collagen or fibronectin and those associated with liver metastasis formation from breast cancer cells with a claudin-2 knockdown versus controls (Figures 3, 4 , 5) were calculated using a Student's t-test. The three weakly-aggressive cell lines carrying the EV control were considered as one group and the three liver-aggressive cell lines as another group. Data grouped from parental or EV populations was compared with the grouped data from both the knockdown populations (KD1 and KD2). For all other experiments, the significance values were obtained using a Wilcoxon test.
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